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Charles F Verge1,2Abstract
Background/Aims: Infants with diabetes insipidus (DI), especially those with impaired thirst mechanism or
hypothalamic hyperphagia, are prone to severe sodium fluctuations, often requiring hospitalization. We aimed to
avoid dangerous fluctuations in serum sodium and improve parental independence.
Methods: A 16-month old girl with central DI, absent thirst mechanism and hyperphagia following surgery for
hypothalamic astrocytoma had erratic absorption of oral DDAVP during chemotherapy cycles. She required
prolonged hospitalizations for hypernatremia and hyponatremic seizure. Intensive monitoring of fluid balance,
weight and clinical assessment of hydration were not helpful in predicting serum sodium. Discharge home was
deemed unsafe. Oral DDAVP was switched to subcutaneous (twice-daily injections, starting with 0.01mcg/dose,
increasing to 0.024mcg/dose). The parents adjusted daily fluid allocation by sliding-scale, according to the blood
sodium level (measured by handheld i-STAT analyser, Abbott). We adjusted the DDAVP dose if fluid allocation
differed from maintenance requirements for 3 consecutive days.
Results: After 2.5 months, sodium was better controlled, with 84% of levels within reference range (135-145 mmol/L)
vs. only 51% on the old regimen (p= 0.0001). The sodium ranged from 132-154 mmol/L, compared to 120–156 on the
old regimen. She was discharged home.
Conclusion: This practical regimen improved sodium control, parental independence, and allowed discharge home.
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Infants treated with DDAVP for diabetes insipidus (DI) are
prone to wide sodium fluctuations, due to uncertainties in
the clinical assessment of hydration status and a high fluid
diet [1]. Infants may drink due to hunger rather than thirst,
leading to dilutional hyponatremia and seizures. Manage-
ment is further complicated in those with impaired thirst
mechanism and/or hypothalamic hyperphagia. Recently
the use of subcutaneous DDAVP [2] and the use of home
sodium monitoring [3] have been reported . We aimed to* Correspondence: s.hameed@UNSW.edu.au
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reproduction in any medium, provided the orimprove sodium control and parental independence using
these in combination with a written sliding-scale fluid
prescription plan.Methods
Patient history
A 16-month old girl developed central DI, absent thirst
mechanism and hypothalamic hyperphagia following
surgery for a large hypothalamic pilomixoid astrocytoma
(6.6 × 7.1 × 6.7 cm). Postoperatively, she developed pro-
found polyuria (up to 20 ml/kg/hr) and received intra-
venous vasopressin infusion in the intensive care ward,
before switching to oral DDAVP. The oral DDAVP was
usually given twice-daily, with the parents awaitingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Sliding-scale fluid prescription given to the
parents to adjust daily fluid prescription according to the





Below 130 100 Telephone and go to ED for
assessment
130-134 500 Repeat sodium level before
PM dose
135-139 800 Repeat sodium level before
PM dose
140-145 1,200 Sodium is in target range
146-150 1,350 Repeat sodium level before
PM dose
151-155 1,500 Repeat sodium level before
PM dose
Over 155 1,800 Telephone and go to ED for
assessment
Parents were instructed to telephone the Paediatric Endocrine department
and attend the emergency department (ED) if levels were below 130 or over
150 mmol/L.
*The fluid prescription is based on 1,200 ml maintenance fluids, with additions
or subtractions based on the formula for calculating water deficit in ml
(600 ×wt(kg) × (1-target [Na]/measured [Na]). If the sodium is >150 mmol/L,
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Figure 1 Scatter plots of sodium levels during 3.9 months on oral
DDAVP (n=106) compared with the subsequent 2.5 months on
the new regimen of twice-daily subcutaneous DDAVP with
sliding scale fluid prescription, adjusted according to the results
of home sodium monitoring (n=98). Median and interquartile
range for sodium levels on each regimen are also shown.
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on an empty stomach. The antidiuretic effect of each
dose varied considerably, necessitating frequent dosage
changes and supplemental doses at various times of the
day and night. The changes in antidiuretic action of
DDAVP were most pronounced during chemotherapy
cycles, possibly reflecting variable absorption of oral
DDAVP from the gastrointestinal tract. Additionally, the
need for intravenous fluid hydration for platinum based
alkylating chemotherapy further complicated fluid
management. Despite intensive monitoring of fluid
balance, weight and clinical assessment of hydration by
experienced clinicians, the serum sodium fluctuated
widely. She was discharged home following prolonged
hospitalization for hypernatremia only to require intensive
care admission the next day following a hyponatremic seiz-
ure. Further discharge home was, therefore, deemed
unsafe.
The patient also had anterior hypopituitarism, treated
with replacement thyroxine (89mcg/m2/day, 4.3mcg/kg/
day) and hydrocortisone (10 mg/m2/day). She had hypo-
thalamic hyperphagia and caloric intake was limited by
the use of a diluted formula. Despite these measures, the
weight standard deviation score increased markedly
from −2.1 SDS pre-operatively to +2.5 SDS 8 months




The hospital laboratory performed sodium measurements
using indirect potentiometry (Beckman Coulter, Fullerton,
USA). Home sodium monitoring was performed daily by
the parents, using a handheld i-STAT analyser (Abbott,
USA). Sodium results by i-STAT correspond well with
laboratory sodium levels by error grid analysis [3]. The
parents collected 95μL of capillary blood onto single use
cartridges, and results were available within 6 minutes.
We compared sodium results for 3.9 months before and
2.5 months following introduction of the new regimen.
DDAVP
DDAVP was switched from oral to subcutaneous (4mcg/ml
diluted 1:10 in normal saline, prepared each week by
hospital pharmacy in glass vials). We found that this prep-
aration remained stable for at least one week (based on the
duration of antidiuretic response). The injections were
administered by the parents twice-daily by insulin syringe,
starting with 0.01mcg/dose (based on 200-times potency vs.
oral), increasing to 0.024mcg/dose (0.003mcg/kg/dose).
Fluid prescription by sliding-scale
Daily oral fluid allocation was adjusted by the parents
using a sliding-scale according to the blood sodiumlevel. We designed the sliding scale using the formula
for water deficit in ml [4], and the parents were supplied
with a written plan (Table 1). We adjusted the DDAVP
dose if the fluid allocation differed from maintenance
requirements for 3 consecutive days. We ceased moni-
toring urine output, which required labour-intensive
weighing of nappies.
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After 2.5 months, the sodium was better controlled, with
82/98 (84%) within reference range (135-145 mmol/L) vs.
only 54/106 (51%) on the old regimen (Chi squared test,
p = 0.0001). The sodium ranged from 132-154 mmol/L,
compared to 120–156 on the old regimen (Figure 1). The
standard deviation of sodium levels was lower on the new
regimen (4.2 mmol/L vs. 7.3 mmol/L on the old regimen).
The patient was successfully discharged home. There
were no further hospital admissions due to sodium
fluctuations. The parents reported a strong preference
for the new regimen. In particular, they were reassured
by the ability to determine the sodium level quickly by i-
STAT. They also preferred the fixed, twice-daily regimen
of DDAVP administration (which avoided the need to
administer DDAVP during their sleeping hours), despite
the need for subcutaneous injection. Furthermore, they
appreciated not having to weigh nappies, which they
found to be laborious, unpleasant and difficult to
perform when away from home. The family also enjoyed
not having to delay feeding following administration of
DDAVP, which was distressing to the infant and had
been a requirement of oral dosing (in an attempt to
improve the reliability of absorption). The i-STAT costs
($10, 000 initially, then $5 per day for consumables)
were less than the cost of her previous hospital admissions,
including intensive care, for hypo and hypernatremia.
Discussion
Oral DDAVP absorption may be impaired when given
with meals [1,5]. Intranasal DDAVP can be difficult to
administer to infants and absorption may be impaired
during coryzal illnesses [5]. Rivkees reported that sub-
cutaneous DDAVP is useful when precise and consistent
dosing is required [5]. Blanco and colleagues [2]
reported a retrospective comparison of 6 infants treated
with subcutaneous DDAVP and 4 treated with intranasal
lysine vasopressin. They found that subcutaneous dosing
resulted in a narrower range of sodium levels and a
higher percentage within the normal range. None of
their patients had impairment of thirst mechanism and
all fed ad libitum.
Green and Landt [3] reported a cross-over study
involving 4 children with DI and impaired thirst
mechnanism (or inability to access water). Home so-
dium monitoring by i-STAT was compared with rou-
tine care (regular laboratory sodium measures weekly
to monthly, and additional measures when clinically
indicated). All carers preferred iSTAT to routine care,
but there was no significant difference in the number
of hospitalisations in the two arms. They recorded
significantly higher number of telephone calls to the
study physician during home sodium monitoring. In
contrast, we found that by providing the parents witha sliding scale fluid prescription, they were able to
manage the DI without needing to call regularly for
advice.
Conclusion
We describe a practical regimen combining subcutaneous
DDAVP and sliding-scale fluid prescription according to
home sodium monitoring levels that improved sodium
control, increased parental independence, and allowed
discharge home.
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